CIK 0001966494
CRGX CARGO Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 23, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at CARGO Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Anup Radhakrishnan See Remarks sell | $105k 27,404 shares | -18% | - | |
| 15Weak | Anup Radhakrishnan See Remarks sell | $6,522 1,629 shares | -2% | - |
Transactions
The last 15 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | Krishnan Viswanadhan director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 23, 2025 |
| Jun 18, 2025 | Abraham Bassan director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 20, 2025 |
| Jun 18, 2025 | John A Orwin director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 20, 2025 |
| Jun 18, 2025 | Jane Henderson director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 20, 2025 |
| Jun 18, 2025 | David Charles Lubner director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 20, 2025 |
| Jun 18, 2025 | Kapil Dhingra director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 20, 2025 |
| Jun 18, 2025 | Reid M Huber director | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 20, 2025 |
| May 14, 2025 | Anup Radhakrishnan See Remarks | SOpen-market sale Common Stock | -27,404 | $3.84 | $105k | 122,413 | May 16, 2025 |
| May 12, 2025 | Anup Radhakrishnan See Remarks | AGrant or award Common Stock | +72,500 | $0.00 | $0 | 149,817 | May 14, 2025 |
| Apr 3, 2025 | Anup Radhakrishnan See Remarks | SOpen-market sale Common Stock | -1,629 | $4.00 | $6,522 | 77,317 | Apr 8, 2025 |
| Mar 14, 2025 | Shishir Gadam Chief Technical Officer | AGrant or award Common Stock | +60,000 | $0.00 | $0 | 89,480 | Mar 18, 2025 |
| Mar 14, 2025 | Gina Chapman President & CEO | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 303,905 | Mar 18, 2025 |
| Mar 14, 2025 | Ginna Laport Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 50,000 | Mar 18, 2025 |
| Mar 14, 2025 | Anup Radhakrishnan See Remarks | AGrant or award Common Stock | +72,500 | $0.00 | $0 | 78,946 | Mar 18, 2025 |
| Nov 15, 2024 | Anup Radhakrishnan See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Nov 15, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Abraham Bassandirector
- Gina ChapmanPresident & CEO
- Kapil Dhingradirector
- Shishir GadamChief Technical Officer
- Jane Hendersoncfo, officer, director
- Reid M Huberdirector
- Ginna LaportChief Medical Officer
- David Charles Lubnerdirector
- John A Orwindirector
- Anup RadhakrishnanSee Remarks
- Krishnan Viswanadhanofficer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.